Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development

IntroductionExperimental and clinical evidence points to a critical role of progesterone and the nuclear progesterone receptor (PR) in controlling mammary gland tumorigenesis. However, the molecular mechanisms of progesterone action in breast cancer still remain elusive. On the other hand, micro RNAs (miRNAs) are short ribonucleic acids which have also been found to play a pivotal role in cancer pathogenesis. The role of miRNA in progestin-induced breast cancer is poorly explored. In this study we explored progestin modulation of miRNA expression in mammary tumorigenesis.MethodsWe performed a genome-wide study to explore progestin-mediated regulation of miRNA expression in breast cancer. miR-16 expression was studied by RT-qPCR in cancer cell lines with silenced PR, signal transducer and activator of transcription 3 (Stat3) or c-Myc, treated or not with progestins. Breast cancer cells were transfected with the precursor of miR-16 and proliferation assays, Western blots or in vivo experiments were performed. Target genes of miR-16 were searched through a bioinformatical approach, and the study was focused on cyclin E. Reporter gene assays were performed to confirm that cyclin E 3'UTR is a direct target of miR-16.ResultsWe found that nine miRNAs were upregulated and seven were downregulated by progestin in mammary tumor cells. miR-16, whose function as a tumor suppressor in leukemia has already been shown, was identified as one of the downregulated miRNAs in murine and human breast cancer cells. Progestin induced a decrease in miR-16 levels via the classical PR and through a hierarchical interplay between Stat3 and the oncogenic transcription factor c-Myc. A search for miR-16 targets showed that the CCNE1 gene, encoding the cell cycle regulator cyclin E, contains conserved putative miR-16 target sites in its mRNA 3' UTR region. We found that, similar to the molecular mechanism underlying progestin-modulated miR-16 expression, Stat3 and c-Myc participated in the induction of cyclin E expression by progestin. Moreover, overexpression of miR-16 abrogated the ability of progestin to induce cyclin E upregulation, revealing that cyclin E is a novel target of miR-16 in breast cancer. Overexpression of miR-16 also inhibited progestin-induced breast tumor growth in vitro and in vivo, demonstrating for the first time, a role for miR-16 as a tumor suppressor in mammary tumorigenesis. We also found that the ErbB ligand heregulin (HRG) downregulated the expression of miR-16, which then participates in the proliferative activity of HRG in breast tumor cells.ConclusionsIn this study, we reveal the first progestin-regulated miRNA expression profile and identify a novel role for miR-16 as a tumor suppressor in progestin- and growth factor-induced growth in breast cancer.

[1]  I. Frahm,et al.  Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity , 2004, Oncogene.

[2]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[3]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[5]  I. Shih,et al.  Cyclin E and p16 Immunoreactivity in Epithelioid Trophoblastic Tumor—An Aid in Differential Diagnosis , 2006, The American journal of surgical pathology.

[6]  Domenico Coppola,et al.  MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.

[7]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[8]  C. Clarke,et al.  Progesterone induces adult mammary stem cell expansion , 2010, Nature.

[9]  K. Hunt,et al.  Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors , 2010, Clinical Cancer Research.

[10]  J. Schelter,et al.  c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster , 2008, Cancer biology & therapy.

[11]  R. Sutherland,et al.  Estrogen and Progestin Regulation of Cell Cycle Progression , 2004, Journal of Mammary Gland Biology and Neoplasia.

[12]  A. Molinolo,et al.  The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. , 2009, Endocrine-related cancer.

[13]  Didier Picard,et al.  miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor α mRNA , 2009, Molecular and Cellular Biology.

[14]  J. Conover,et al.  Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. , 2000, Biochemical and biophysical research communications.

[15]  Isabelle Bedrosian,et al.  Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.

[16]  P. Leder,et al.  NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. , 1996, Oncogene.

[17]  A. Kornblihtt,et al.  Progestins Induce Transcriptional Activation of Signal Transducer and Activator of Transcription 3 (Stat3) via a Jak- and Src-Dependent Mechanism in Breast Cancer Cells , 2005, Molecular and Cellular Biology.

[18]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[19]  C. Croce,et al.  SnapShot: MicroRNAs in Cancer , 2009, Cell.

[20]  J. Pollard,et al.  Edinburgh Research Explorer Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium , 2022 .

[21]  D. Liao,et al.  c-Myc in breast cancer. , 2000, Endocrine-related cancer.

[22]  Dan Grandér,et al.  DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. , 2009, Experimental cell research.

[23]  K. Hunt,et al.  Cyclin E deregulation is an early event in the development of breast cancer , 2009, Breast Cancer Research and Treatment.

[24]  C. Pasqualini,et al.  Hormone dependence of a mouse mammary tumor line inducedin vivo by medroxyprogesterone acetate , 1990, Breast Cancer Research and Treatment.

[25]  Sarat Chandarlapaty,et al.  Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients , 2011, Proceedings of the National Academy of Sciences.

[26]  C. Croce,et al.  MicroRNAs in cancer: personalizing diagnosis and therapy , 2010, Annals of the New York Academy of Sciences.

[27]  Andrea Califano,et al.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. , 2010, Cancer cell.

[28]  D. Edwards,et al.  Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. , 2001, Molecular cell.

[29]  Xiang-Dong Fu,et al.  Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. , 2009, BMB reports.

[30]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[31]  Tongbin Li,et al.  miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..

[32]  C. Croce,et al.  microRNA-205 regulates HER3 in human breast cancer. , 2009, Cancer research.

[33]  Laurent Meijer,et al.  Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. , 2011, Cancer research.

[34]  C. Lange,et al.  The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. , 2010, Molecular endocrinology.

[35]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[36]  L. Meijer,et al.  Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression , 2009, Cell cycle.

[37]  M. Sogayar,et al.  Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation , 2006, Oncogene.

[38]  M. Tkach,et al.  Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer , 2011, Steroids.

[39]  J. Mendell,et al.  Myc: Maestro of MicroRNAs. , 2010, Genes & cancer.

[40]  R. Ullrich,et al.  Progesterone facilitates chromosome instability (aneuploidy) in p53 null , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  Y. Li,et al.  Prevention of Brca1-Mediated Mammary Tumorigenesis in Mice by a Progesterone Antagonist , 2006, Science.

[42]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  N. Krett,et al.  Steroid receptor and microRNA regulation in cancer , 2010, Current opinion in oncology.

[44]  R. Lupu,et al.  Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. , 2003, Molecular cancer research : MCR.

[45]  Michael T. McManus,et al.  Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion* , 2009, The Journal of Biological Chemistry.

[46]  S. Haslam,et al.  Postmenopausal Hormone Replacement Therapy: Effects on Normal Mammary Gland in Humans and in a Mouse Postmenopausal Model , 2004, Journal of Mammary Gland Biology and Neoplasia.

[47]  D. Edwards.  Regulation of signal transduction pathways by estrogen and progesterone. , 2005, Annual review of physiology.

[48]  T. Brunner,et al.  miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. , 2009, Cancer research.

[49]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[50]  C. Balduini,et al.  Identification and biochemical characterization of Rap2C, a new member of the Rap family of small GTP-binding proteins. , 2006, Biochimie.

[51]  Robert A. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer (Nature (2007) 449, (682-688)) , 2008 .

[52]  Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. , 1993 .

[53]  George A Calin,et al.  MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. , 2009, Cancer research.

[54]  M. Hung,et al.  ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells , 2009, Molecular Cancer Research.

[55]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[56]  J. Manson,et al.  Breast cancer after use of estrogen plus progestin in postmenopausal women. , 2009, The New England journal of medicine.

[57]  C. Lange,et al.  Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. , 1999, Molecular endocrinology.

[58]  L. Kastl,et al.  miRNA-34a is associated with docetaxel resistance in human breast cancer cells , 2011, Breast Cancer Research and Treatment.

[59]  K. Horwitz,et al.  Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.

[60]  R. Lupu,et al.  Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas , 1999, Oncogene.

[61]  W. Béguelin,et al.  Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth , 2008, Molecular and Cellular Biology.

[62]  D. Cittelly,et al.  Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors , 2010, Carcinogenesis.

[63]  K. Horwitz,et al.  Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. , 1993, Molecular endocrinology.

[64]  I. Frahm,et al.  TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways , 2008 .

[65]  M. Tkach,et al.  Progesterone Receptor Induces ErbB-2 Nuclear Translocation To Promote Breast Cancer Growth via a Novel Transcriptional Effect: ErbB-2 Function as a Coactivator of Stat3 , 2010, Molecular and Cellular Biology.

[66]  Wen-rong Gong,et al.  Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross‐talk with estrogen receptor , 1998, The EMBO journal.

[67]  D. Cittelly,et al.  Steroid receptors and microRNAs: Relationships revealed , 2011, Steroids.

[68]  H. Verkooijen,et al.  The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. , 2009, Maturitas.

[69]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[70]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[71]  Guohua Wang,et al.  Estradiol-regulated microRNAs control estradiol response in breast cancer cells , 2009, Nucleic acids research.

[72]  P. Elizalde,et al.  Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells , 2001, Oncogene.

[73]  P. Elizalde,et al.  Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors. , 2001, Experimental cell research.

[74]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[75]  M. Tkach,et al.  Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation , 2010, Breast Cancer Research and Treatment.

[76]  K. Horwitz,et al.  Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). , 1997, Molecular endocrinology.

[77]  C. Croce,et al.  MiR-15a and miR-16-1 cluster functions in human leukemia , 2008, Proceedings of the National Academy of Sciences.

[78]  Yusuke Yamamoto,et al.  Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  B. Jacobsen,et al.  Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer , 2012, Molecular and Cellular Endocrinology.

[80]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[81]  A. Molinolo,et al.  Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. , 2006, The American journal of pathology.

[82]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[83]  Susan A Kadlubar,et al.  Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells , 2012, BMC Cancer.

[84]  D. Edwards,et al.  A sequence in the 5′ flanking region confers progestin responsiveness on the human c-myc gene , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[85]  F. DeMayo,et al.  Progesterone involvement in breast development and tumorigenesis—as revealed by progesterone receptor “knockout” and “knockin” mouse models , 2003, Steroids.

[86]  X. Zhang,et al.  Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas , 2012, Oncogene.

[87]  R. Brekken,et al.  Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. , 2007, Cancer research.

[88]  R. Arlinghaus,et al.  Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. , 2005, Cancer research.

[89]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[90]  D. Edwards,et al.  Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. , 2007, Molecular endocrinology.

[91]  M. Ellersieck,et al.  Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice , 2010, Menopause.

[92]  Zhang,et al.  Oncogenic Wip1 Phosphatase Is Inhibited by miR-16 in the DNA Damage Signaling Pathway , 2010 .

[93]  C. Benz,et al.  Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b* , 2007, Journal of Biological Chemistry.